All In Biotech

Drug Trial Radar · NCT07862582

RYZ711 Diagnostic Platform Study

Phase 1 /2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
RayzeBio, Inc.Industry
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.

Conditions

  • Prostate Cancer (Adenocarcinoma)
  • Adenocarcinoma of the Prostate
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Biochemical Recurrence (BCR)
  • High-Risk Localized Prostate Cancer

Interventions

  • RYZ711Drug

    RYZ711 PET/CT; PSMA PET/CT

  • PSMA PET/CTDiagnostic test

    RYZ711 PET/CT; PSMA PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEs, SAEs, and Adverse Events of Special Interest (AESIs)Time frame: From informed consent up to 3 months post-RYZ711 PET/CT
  2. Concordance Rate of RYZ711 PET/CT Compared with PSMA PET/CTTime frame: Up to 3 months post-RYZ711 PET/CT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Facility

    Omaha, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.